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doi:10.1016/j.ejvs.2011.07.013Abstract Objective: The study aimed to test the potential role of insulin-like growth factor I
(IGF-I) and IGF-II as biomarkers for abdominal aortic aneurysm (AAA).
Methods and results: IGF-I and II levels were analysed in 115 patients with screening diagnosed
AAA kept under annual surveillance for 10 years.
Serum IGF-I correlated positively with AAA size and growth rate (r Z 0.23, P Z 0.016 and
r Z 0.27, P Z 0.004), persisting after adjustment for potential confounders.
Serum IGF-I level predicted cases needing later surgery (AOC: 0.63; 95% confidence interval:
0.52e0.73).
Conclusions: In this prospective, long-term study, baseline serum IGF-I correlated positively
with AAA size and growth rate and predicted future need for preventive surgery.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.For at least a decade, insulin-like growth factor I (IGF-I) has
been considered to be a mediator of cardiovascular disease
(CVD). However, more recently and increasingly, experi-
mental and epidemiological studies suggest that IGF-I may
in fact be a vascular protective factor.1
The role of IGF-I and IGF-II in patients with abdominal
aortic aneurysm (AAA) is unknown. Consequently, this study927 2447.
rg.rm.dk (J.S. Lindholt).
ty for Vascular Surgery. Publisheaimed to investigate whether IGF-I and -II were associated
to AAA growth rate, as well as being associated with
cardiovascular events for this group of patients with a well-
known high risk for CVD.Material and Methods
A total of 115 small AAAs detected by population-based
screening in 1994e98 were kept under annual surveillance.d by Elsevier Ltd. All rights reserved.
Serum IGF-I Predicts Aneurysmal Progression 561Deaths were identified in the Danish Civil Register. All
previous discharge diagnoses were recorded in the National
Hospital Discharge Registry concerning cardiovascular (CV)
events.
The expansion rate was calculated by individual linear
regression analysis.Figure 1 Serological findings. A. Scatter plot of S-IGF-I vs.
mean growth rate (r Z 0.27, P Z 0.004). If the outlier with
a growth rate close to 10 mm/year is omitted: r Z 0.30,
P Z 0.002. B. ROC-curve analysis of serum IGF-I levels and
need for surgery. AUC: 0.63, 95% C.I. 0.52e0.73, p Z 0.013.Total IGF-I and -II levels were measured by validated, in-
house time-resolved immunofluorometric assays. The in-
house assays have an intra- and inter-assay coefficient of
variation (CV) averaging <5% and 10%, respectively.2
Informed consent was obtained from all subjects before
participation, and the study was approved by the Local
Ethics Committee.Statistics
Univariate Pearson’s correlation analyses were used to
examine the associations between continuous variables
combined multiple linear regression analysis adjusting for
known and potential confounders, such as current smoking,
body mass index, previous CV events, use of glucocorti-
coids, low dose aspirin, b-blockers or angiotensin-
converting enzyme (ACE) inhibitors, ankleebrachial; index
(ABI) and AAA size, respectively.
Receiver operating characteristic (ROC)-curve analyses
were used to test prediction of later surgery. In addition,
IGF tertiles were used to quantify the predictive value
concerning need for surgery without and with adjustment
for the earlier mentioned potential confounders by Cox’s
regression analysis.Figure 2 Survival curves for need for later surgery and the
IGF-I tertiles. Crude HR Z 1.49, 95% C.I.: 1.02; 2.17. Adjusted
HR Z 2.28, 95% C.I.: 1.37; 3.78.
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The mean (SD) AAA size and growth rate was 43.4 (7.23)
mm and 2.82 (2.11) mm year1, respectively. During
surveillance, 37 patients died and 45 were referred to
surgery.
Serum IGF-I, but not IGF-II, correlated positively with
AAA size and AAA growth (r Z 0.23, P Z 0.016 and
r Z 0.27, P Z 0.004, respectively (Fig. 1(A))), persisting
after confounder adjustment.
By ROC-curve analysis, serum IGF-I levels were predic-
tive for cases in need for later preventive surgery (AUC
0.63, 95% confidence interval (CI) 0.52e0.73; Fig. 1(B)).
The adjusted growth rate increased by 0.53  0.23 mm
annually between the IGF-1 tertiles (P Z 0.013). The
adjusted risk of needing later surgery increased more than
two times between the IGF-1 tertiles (Crude hazard ratio
(HR) Z 1.49, 95% CI: 1.02; 2.17, Adjusted HR Z 2.28, 95%
C.I.: 1.37; 3.78) (Fig. 2).
Serum IGF-I did not correlate with ABI and showed no
predictive potential to predict either death or cardiovas-
cular events. No significant associations were noticed con-
cerning serum IGF-II.
Discussion
Based on these findings, we speculate that circulating IGF-I
levels may serve as a novel biomarker for the natural
history of AAA. The strength of this study is the length of
follow-up (10 years), using population-based prospective
data and a standardised follow-up with a small inter-
observer variation of the measurements. Obviously, some
influence of selection bias cannot be excluded. Informationbias seems unlikely as follow-up data were obtained blin-
ded from IGF results. However, as any other observational
study, there is a risk of residual confounding in spite of
extensive adjustment for potential confounders.
Disclosure Statement
The authors have nothing to disclose.
Conflict of Interest
None.Acknowledgements
Financial support for the study was provided by The Danish
Heart Foundation, The Rosa and Asta Jensen Foundation,
The Danish Research Council for Health and Disease, The
Health Department of Viborg County and the 7th European
Framework Programme: Health-2007-2.4.2-2; project title:
Fighting Aneurysmal Disease. Grant agreement no: 200647.References
1 Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low
serum insulin-like growth factor I is associated with increased
risk of ischemic heart disease: a population-based case-control
study. Circulation 2002;106:939e44.
2 Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved
immunofluorometric assays for determination of human insulin-
like growth factor I and II. Growth Regul 1995;5:169e76.
